# Zivo Bioscience, Inc.: financial statements, quarterly

ZIVO · OTC · CIK 1101026 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/zivo.md) · [Financials](/companies/zivo/financials.md) · [Filings](/companies/zivo/filings.md) · [Insiders](/companies/zivo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/zivo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0 d](/filings/0001654954-24-003228.md) | [0.0](/filings/0001654954-24-006082.md) | [4.1](/filings/0001654954-24-010644.md) | [11.8](/filings/0001654954-24-014463.md) | [11.8 d](/filings/0001654954-25-002948.md) | [35.7](/filings/0001654954-25-005748.md) | [0.0](/filings/0001654954-25-009650.md) | [31.5](/filings/0001654954-25-013095.md) | [90.0 d](/filings/0001654954-25-002948.md) | [0.0](/filings/0001654954-25-005748.md) | [53.4](/filings/0001654954-25-009650.md) | [65.6](/filings/0001654954-25-013095.md) |
| Cost of revenue | $k | [0.0 d](/filings/0001654954-24-003228.md) | [0.0](/filings/0001654954-24-006082.md) | [0.7](/filings/0001654954-24-010644.md) | [7.7](/filings/0001654954-24-014463.md) | [7.7 d](/filings/0001654954-25-002948.md) | [23.2](/filings/0001654954-25-005748.md) | [0.0](/filings/0001654954-25-009650.md) | [22.1](/filings/0001654954-25-013095.md) | [63.0 d](/filings/0001654954-25-002948.md) | [0.0](/filings/0001654954-25-005748.md) | [35.5](/filings/0001654954-25-009650.md) | [44.3](/filings/0001654954-25-013095.md) |
| Gross profit | $k | [0.0 d](/filings/0001654954-24-003228.md) | [0.0](/filings/0001654954-24-006082.md) | [3.3](/filings/0001654954-24-010644.md) | [4.1](/filings/0001654954-24-014463.md) | [4.1 d](/filings/0001654954-25-002948.md) | [12.5](/filings/0001654954-25-005748.md) | [0.0](/filings/0001654954-25-009650.md) | [9.5](/filings/0001654954-25-013095.md) | [27.0 d](/filings/0001654954-25-002948.md) | [0.0](/filings/0001654954-25-005748.md) | [17.9](/filings/0001654954-25-009650.md) | [21.3](/filings/0001654954-25-013095.md) |
| Research and development | $k | [519 d](/filings/0001654954-24-003228.md) | [402](/filings/0001654954-24-006082.md) | [442](/filings/0001654954-24-010644.md) | [221](/filings/0001654954-24-014463.md) | [312 d](/filings/0001654954-25-002948.md) | [313](/filings/0001654954-25-005748.md) | [2,252](/filings/0001654954-25-009650.md) | [326](/filings/0001654954-25-013095.md) | [243 d](/filings/0001654954-25-002948.md) | [2,769](/filings/0001654954-25-005748.md) | [480](/filings/0001654954-25-009650.md) | [203](/filings/0001654954-25-013095.md) |
| Operating income | $k | [(2,638) d](/filings/0001654954-24-003228.md) | [(1,970)](/filings/0001654954-24-006082.md) | [(1,824)](/filings/0001654954-24-010644.md) | [(1,572)](/filings/0001654954-24-014463.md) | [(1,897) d](/filings/0001654954-25-002948.md) | [(1,276)](/filings/0001654954-25-005748.md) | [(8,230)](/filings/0001654954-25-009650.md) | [(2,260)](/filings/0001654954-25-013095.md) | [(1,596) d](/filings/0001654954-25-002948.md) | [(4,209)](/filings/0001654954-25-005748.md) | [(1,633)](/filings/0001654954-25-009650.md) | [(1,018)](/filings/0001654954-25-013095.md) |
| Interest expense | $k | [3.0 d](/filings/0001654954-24-003228.md) | [3.0](/filings/0001654954-24-006082.md) | [31.8](/filings/0001654954-24-010644.md) | [32.7](/filings/0001654954-24-014463.md) | [(43.7) d](/filings/0001654954-24-003228.md) | [2.6](/filings/0001654954-25-005748.md) | [6.8](/filings/0001654954-25-009650.md) | [8.6](/filings/0001654954-25-013095.md) | not reported | [2.4](/filings/0001654954-25-005748.md) | [7.4](/filings/0001654954-25-009650.md) | [13.0](/filings/0001654954-25-013095.md) |
| Income tax | $k | not reported | [0.0](/filings/0001654954-24-006082.md) | [0.0 d](/filings/0001654954-24-010644.md) | [0.0 d](/filings/0001654954-24-014463.md) | not reported | [0.0](/filings/0001654954-24-006082.md) | [0.0 d](/filings/0001654954-24-010644.md) | [0.0 d](/filings/0001654954-24-014463.md) | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,641) d](/filings/0001654954-24-003228.md) | [(1,973)](/filings/0001654954-24-006082.md) | [(2,071)](/filings/0001654954-24-010644.md) | [(1,825)](/filings/0001654954-24-014463.md) | [(1,909) d](/filings/0001654954-25-002948.md) | [(1,278)](/filings/0001654954-25-005748.md) | [(8,236)](/filings/0001654954-25-009650.md) | [(2,269)](/filings/0001654954-25-013095.md) | [(1,601) d](/filings/0001654954-25-002948.md) | [(4,211)](/filings/0001654954-25-005748.md) | [(1,640)](/filings/0001654954-25-009650.md) | [(1,033)](/filings/0001654954-25-013095.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | [(0.47)](/filings/0001654954-25-005748.md) | [(2.78)](/filings/0001654954-25-009650.md) | [(0.67)](/filings/0001654954-25-013095.md) | not reported | [(1.12)](/filings/0001654954-25-005748.md) | [(0.43)](/filings/0001654954-25-009650.md) | [(0.27)](/filings/0001654954-25-013095.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [1,799](/filings/0001654954-23-002845.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $k | [1,902](/filings/0001654954-24-003228.md) | [928](/filings/0001654954-23-006097.md) | [530](/filings/0001654954-23-010769.md) | [1,948](/filings/0001654954-23-014165.md) | [425](/filings/0001654954-25-002948.md) | [711](/filings/0001654954-24-006082.md) | [495](/filings/0001654954-24-010644.md) | [437](/filings/0001654954-24-014463.md) | [1,635](/filings/0001654954-25-013095.md) | [1,023](/filings/0001654954-25-005748.md) | [410](/filings/0001654954-25-009650.md) | [281](/filings/0001654954-25-013095.md) |
| Total assets | $k | [2,123](/filings/0001654954-24-003228.md) | [1,128](/filings/0001654954-23-006097.md) | [710](/filings/0001654954-23-010769.md) | [2,102](/filings/0001654954-23-014165.md) | [556](/filings/0001654954-25-002948.md) | [816](/filings/0001654954-24-006082.md) | [576](/filings/0001654954-24-010644.md) | [496](/filings/0001654954-24-014463.md) | [1,643](/filings/0001654954-25-013095.md) | [1,331](/filings/0001654954-25-005748.md) | [703](/filings/0001654954-25-009650.md) | [559](/filings/0001654954-25-013095.md) |
| Current liabilities | $k | [2,028](/filings/0001654954-24-003228.md) | [2,791](/filings/0001654954-23-006097.md) | [3,804](/filings/0001654954-23-010769.md) | [3,174](/filings/0001654954-23-014165.md) | [2,762](/filings/0001654954-25-002948.md) | [3,085](/filings/0001654954-24-006082.md) | [2,871](/filings/0001654954-24-010644.md) | [2,579](/filings/0001654954-24-014463.md) | [2,042](/filings/0001654954-25-013095.md) | [2,613](/filings/0001654954-25-005748.md) | [2,960](/filings/0001654954-25-009650.md) | [3,614](/filings/0001654954-25-013095.md) |
| Total liabilities | $k | [2,134](/filings/0001654954-24-003228.md) | [2,870](/filings/0001654954-23-006097.md) | [3,855](/filings/0001654954-23-010769.md) | [3,196](/filings/0001654954-23-014165.md) | [2,762](/filings/0001654954-25-002948.md) | [3,085](/filings/0001654954-24-006082.md) | [2,871](/filings/0001654954-24-010644.md) | [2,579](/filings/0001654954-24-014463.md) | [2,158](/filings/0001654954-25-013095.md) | [2,949](/filings/0001654954-25-005748.md) | [3,244](/filings/0001654954-25-009650.md) | [3,846](/filings/0001654954-25-013095.md) |
| Current portion of debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $k | [(10.6)](/filings/0001654954-25-002948.md) | [(1,742)](/filings/0001654954-24-010644.md) | [(3,145)](/filings/0001654954-24-014463.md) | [(1,094)](/filings/0001654954-24-014463.md) | [(2,206)](/filings/0001654954-25-013095.md) | [(2,269)](/filings/0001654954-25-009650.md) | [(2,296)](/filings/0001654954-25-013095.md) | [(2,083)](/filings/0001654954-25-013095.md) | [(515)](/filings/0001654954-25-013095.md) | [(1,617)](/filings/0001654954-25-009650.md) | [(2,541)](/filings/0001654954-25-013095.md) | [(3,287)](/filings/0001654954-25-013095.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,447) d](/filings/0001654954-24-003228.md) | [(2,129)](/filings/0001654954-24-006082.md) | [(986) d](/filings/0001654954-24-010644.md) | [(1,970) d](/filings/0001654954-24-014463.md) | [(716) d](/filings/0001654954-25-002948.md) | [(1,699)](/filings/0001654954-25-005748.md) | [(624) d](/filings/0001654954-25-009650.md) | [(1,085) d](/filings/0001654954-25-013095.md) | [(906) d](/filings/0001654954-25-002948.md) | [(1,430)](/filings/0001654954-25-005748.md) | [(476) d](/filings/0001654954-25-009650.md) | [(267) d](/filings/0001654954-25-013095.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q1 FY2014 (2014-03-31) | Q2 FY2014 (2014-06-30) | Q1 FY2015 (2015-03-31) | Q2 FY2015 (2015-06-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [154](/filings/0001078782-15-000752.md) | [125](/filings/0001078782-15-001298.md) | [130](/filings/0001078782-15-000752.md) | [130](/filings/0001078782-15-001298.md) | [2.7](/filings/0001654954-25-005748.md) | [3.0](/filings/0001654954-25-009650.md) | [3.4](/filings/0001654954-25-013095.md) | [3.8](/filings/0001654954-25-005748.md) | [3.8](/filings/0001654954-25-009650.md) | [3.8](/filings/0001654954-25-013095.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,888,595 at 2025-11-09, from the cover of the [10-Q filed 2025-11-14](/filings/0001654954-25-013095.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.